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Introduction
TNF-related apoptosis-inducing ligand (TRAIL) is a
member of the TNF superfamily, which plays an important
role in regulating cell death and inflammation. Beyond its
anti-tumor activity, increasing evidence in animal studies
suggests that TRAIL plays a role in the control of au-
toimmune diseases, and in particular in type 1 diabetes
mellitus (T1DM) [1, 2]. In this context, in a previous study
carried out in a retrospective cohort of T1DM pediatric
patients, we found significant lower levels of circulating
TRAIL in T1DM patients with respect to healthy age-
matched controls [3]. However, a limitation of our previous
study was as follows: (1) the lack of serial serum samples
harvested from the same patients at different time post
onset and (2) the lack of information about concurrent
metabolic status at time of blood sampling.
On these bases, the aim of the present study was to
analyze the evolution of circulating TRAIL levels in a pilot
group of pediatric patients admitted at Emergency
Department for T1DM, from the time of hospital admission
throughout the re-establishment of a normal metabolic
balance and up to 18 months of clinical follow-up. More-
over, the serum levels of TRAIL in T1DM patients were
analyzed in relation to the metabolic status determined at
the same times.
Materials and methods
Patients and sample collection
A total of 80 blood samples were obtained from 11 pe-
diatric patients (Table 1) admitted for T1DM onset or
secondary diabetic ketoacidosis (DKA) at the Emergency
Department of the Institute for Maternal and Child Health
‘‘Burlo Garofolo’’ of Trieste (Italy). For all patients, in-
cluding patient 7, which was overweight ([85th centile)
and had high non-fasting C-peptide levels, the presence of
diabetes-associated autoantibodies together with the lack
of signs of insulin resistance (i.e. acanthosis nigricans),
reasonably excluded T2DM, as well as monogenic dia-
betes. Blood samples were taken at admission and, in case
of DKA, serial blood samples were harvested as per
protocol until stabilization. Additional blood samples were
taken from each patient before hospital discharge and
every 3–6 months during the clinical follow-up. Parents
provided informed consent to blood sample drawing for
research purposes, in accordance with the Declaration of
Helsinki of 1975. The study was approved by the
Bioethics Committee of the IRCCS ‘‘Burlo Garofolo’’
(Trieste, Italy; RC 18/13).
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Laboratory analyses and TRAIL ELISA assays
Blood samples were collected into heparinized tubes. All
biochemical laboratory tests were performed in Burlo
clinical laboratories by using standard commercial kits and
following manufacturers’ instructions. Patients demo-
graphic characteristics, as well as laboratory/clinical data
and treatment, were retrieved from medical records. Serum
TRAIL was measured on frozen serum aliquots by using a
commercially available ELISA kit (R&D Systems, Min-
neapolis, MN) following the manufacturer’s instructions,
as previously described [3].
Statistical analysis
Differences between values at two different time points
were evaluated with a pairwise sign-rank Wilcoxon’s test.
Correlation coefficients were calculated with the Spear-
man’s rank coefficient rho. A p value\0.05 was consid-
ered statistically significant, after applying a Bonferroni
correction if multiple rank-correlations were calculated
simultaneously.
Results
The main demographical and clinical characteristics of
the pediatric patients enrolled in the present study are
summarized in Table 1. Comparative analysis of the
circulating TRAIL levels, showed median TRAIL level at
admission of 52.8 pg/ml (mean ± SD 57.2 ± 27.1 pg/
ml), with the lowest levels measured in the patients with
DKA. Of interest, in all patients included in the study, we
documented a significant increase of TRAIL levels
(p\ 0.01, using the sign-rank pairwise Wilcoxon test) at
the time of discharge, with a median value of 100.3 pg/ml
(mean ± SD 109.8 ± 33.9 pg/ml) (Fig. 1a). Of interest, a
further significant (p\ 0.05) increase was documented
after 6 months, reaching median values of TRAIL of
147.3 pg/ml (mean ± SD 146.1 ± 37.1 pg/ml) that were
maintained without significant modulations also in the
subsequent time points/assessments up to 18 months
(Fig. 1a).
As for clinical protocol, in the patients with DKA
(n = 6) upon admission between 5 and 10, blood sam-
ples were taken for each subject before reaching nor-
malization of venous blood gas (VBG) and/or blood
glucose (BG). This allowed us to monitor TRAIL levels
also at the time points corresponding to metabolic sta-
bilization (median time between admission and stabi-
lization of 15.5 h; IQR 10.1–20.9). Analysis of TRAIL
levels in relationship with all the clinical/metabolic pa-
rameters reported in Table 1 revealed a significant
(p\ 0.05) correlation only between TRAIL levels and:
HCO3 (Spearman’s rank correlation, q = 0.4944,
p = 0.0014; Fig. 1b), BE (q = 0.4405, p = 0.0044;
Fig. 1b), pH (q = 0.368, p = 0.0193), pCO2
(q = 0.3962 p = 0.0114).
Table 1 Characteristics of the subjects included in the study
Patient Sex Age Pubertal
status
BMI BMI
SDS
Admission DKAa BG pH HCO3 HbA1c C-
peptide
Insulin
requirement
1 F 14.3 Post-pubertal 26.03 ?1.42 Secondary DKA Severe 753 6.96 6 8–64 N/A 0.65
2 M 13.7 In established
puberty
20.20 -0.17 Secondary DKA Mild 291 7.26 14 9.6–81 N/A 0.60
3 M 8.6 Pre-pubertal 14.38 -0.62 New onset Moderate 302 7.12 13 13.3–122 0.26 0.70
4 M 12.2 In established
puberty
14.76 -2.06 New onset Moderate 567 7.2 10 11.8–105 0.25 0.85
5 F 7.0 Pre-pubertal 18.94 ?0.98 New onset Moderate 343 7.18 11 12.2–110 0.35 0.94
6 F 5.8 Pre-pubertal 13.91 -1.38 New onset Mild 570 7.34 11.5 10.7–93 N/A 0.97
7 M 12.6 In established
puberty
26.05 ?1.48 New onset None 398 7.45 25 8.6–70 2.56 0.20
8 F 11.6 In established
puberty
16.22 -1.25 New onset None 593 7.56 24 11.3–100 0.67 0.75
9 F 16.8 Post-pubertal 16.10 -2.63 New onset None 394 7.44 25 8.3–67 0.59 0.52
10 M 9.8 Pre-pubertal 14.85 -1.49 New onset None 270 7.32 17 12.0–108 0.21 0.75
11 M 9.8 Pre-pubertal 16.74 -0.45 New onset None 367 7.41 24 9.7–83 0.37 0.31
BMI body mass index (kg/m2), BMI SDS body mass index standard deviation score, BG blood glucose (mg/dl), HbA1c glycated hemoglobin
(%—mmol/mol)
HCO3 (mEq/l), C-peptide (ng/ml), Insulin requirement (U/kg/day)
a DKA was defined: ‘‘mild’’, if pH was 7.2–7.3 and HCO3 10–15 mEq/l; ‘‘moderate’’, if pH was 7.1–7.2 and HCO3 5–10 mEq/l; ‘‘severe’’, if pH
was\7.1 and HCO3\ 5 mEq/l
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Discussion
In both newly diagnosed T1DM and in secondary DKA
pediatric patients, we documented a significant increase of
serum TRAIL levels after short-standing insulin treatment
has been established. Moreover, the circulating levels of
TRAIL correlated with the metabolic parameters. To our
knowledge, this is the first report demonstrating a rapid
modulation of circulating TRAIL during the first hours
after T1DM onset and/or DKA and its relationship with the
metabolic status, further supporting a link between TRAIL
and T1DM. In particular, even if carried out in a small
cohort, our pilot study can strongly suggest the link be-
tween TRAIL and the metabolic status, because (1) a worst
metabolic status (documented by HCO3, BE, pH and CO2
assessments) is associated with lower TRAIL levels, and
(2) improvement in TRAIL levels is seen shortly upon
metabolic stabilization. A potential molecular mechanism
that links metabolic state and circulating levels of TRAIL
might be represented by C reactive protein (CRP). Indeed,
it has been shown that CRP is elevated in children with
newly diagnosed T1DM and DKA crisis and that it likely
enhances inflammation process by modulating a variety of
cytokines [4]. In particular, it has been reported that CRP is
able to up-regulate pro-inflammatory cytokines IL-6, IL-8
and TNF-a, and also to decrease IL-10 secretion. Likewise,
we have previously documented that TRAIL expression
and release is down-regulated by CRP [5]. Although the
Fig. 1 Evolution of the circulating TRAIL levels in relation to the
clinical/metabolic status of T1DM patients. a Circulating TRAIL
levels were monitored in serum samples collected at the indicated
time points of the clinical history of the T1DM pediatric patients
enrolled in the study (n = 11). Horizontal bars are median, upper and
lower edges of box are 75th and 25th percentiles, lines extending from
box are 10th and 90th percentiles. *p\ 0.01 compared to admission;
**p\ 0.05 compared to discharge. b Correlation analyses between
TRAIL circulating levels and clinical parameters related to the
metabolic status of patients. Positive correlation between TRAIL and
base excess (BE) as well as between TRAIL and bicarbonate (HCO3)
are shown. Correlation coefficients, calculated by Spearman’s
analysis, are reported for each correlation in the text
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mechanism underlining the down-regulation of TRAIL in
T1DM should be further investigated, these findings sug-
gest how the metabolic endangerment, rather than au-
toimmunity, is clearly linked to the decrease in the
circulating levels of TRAIL.
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